Attunio Health has recently expanded its precision psychiatry platform by partnering with Quest Diagnostics and Getlabs, enhancing its AI-driven, biomarker-focused approach to mental healthcare.
Following its recent launch, Attunio Health has selected Quest Diagnostics as its primary laboratory partner and integrated Getlabs for at-home blood collection services. This strategic move aims to create a comprehensive infrastructure that supports continuous, data-driven psychiatric care, moving away from traditional episodic treatment models. By leveraging AI, wearable devices, and genetic testing, Attunio seeks to deliver a more objective understanding of mental health conditions.
The collaboration with Quest Diagnostics allows Attunio to provide advanced diagnostic testing across the U.S., enabling clinicians to identify biological factors affecting mental health, such as metabolic issues, inflammation, and hormonal imbalances. Meanwhile, Getlabs facilitates convenient specimen collection, reducing barriers to accessing vital diagnostic information.
Attunio’s innovative model, termed Closed-Loop Precision Psychiatry™, utilizes real-time data to inform treatment decisions, addressing questions that conventional psychiatric practices may overlook. As interest in AI and precision medicine grows, Attunio aims to transform mental healthcare into a predictive and personalized approach, enhancing outcomes for various conditions like ADHD and anxiety.
This expansion underscores the potential for integrating technology and diagnostics in mental health, suggesting a shift towards proactive and measurable care that could redefine how psychiatric conditions are managed in the future.